{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:16:21Z","timestamp":1777954581633,"version":"3.51.4"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>\n                    We present an advanced mCRPC case treated with combined [\n                    <jats:sup>177<\/jats:sup>\n                    Lu]Lu-PSMA-617 and [\n                    <jats:sup>223<\/jats:sup>\n                    Ra]Radiumdichloride. The regimen was well tolerated, with mild xerostomia, fatigue (CTCAE 1), and moderate anemia (CTCAE 2). Initial imaging and serologic parameters demonstrated a favorable treatment response; however, subsequent evaluations showed progression driven by a dedifferentiated pelvic recurrence, increasingly FDG-avid osseous lesions, and new PSMA-negative lymph node metastases. Early biochemical improvement, including PSA and alkaline phosphatase decline, later transitioned to progression consistent with imaging. This case highlights the feasibility and safety of dual \u03b1\/\u03b2\n                    <jats:sup>-<\/jats:sup>\n                    radionuclide therapy in heavily pretreated mCRPC.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006364","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:00:52Z","timestamp":1771858852000},"page":"514-515","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Combined [223Ra]Radiumdichloride and [177Lu]Lu-PSMA-617 Therapy in End-stage Metastatic Castration-resistant Prostate Cancer"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-4880","authenticated-orcid":false,"given":"Martin J.","family":"H\u00fcgle","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Dierks","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Steinestel","sequence":"additional","affiliation":[{"name":"Bavarian Cancer Research Center (BZKF)"},{"name":"Department of Urology, Faculty of Medicine, University of Augsburg, Augsburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Lapa","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Faculty of Medicine, University of Augsburg"},{"name":"Bavarian Cancer Research Center (BZKF)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"R1-20260504","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"The Lancet"},{"key":"R2-20260504","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R3-20260504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","article-title":"Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials","volume":"123","author":"Marcu","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R4-20260504","doi-asserted-by":"crossref","first-page":"101543","DOI":"10.1016\/j.tranon.2022.101543","article-title":"Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines","volume":"26","author":"Abramenkovs","year":"2022","journal-title":"Transl Oncol"},{"key":"R6-20260504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"R7-20260504","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R8-20260504","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:01:16Z","timestamp":1777921276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006364","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-11-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}